BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 18356138)

  • 1. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.
    Mahner S; Schirrmacher S; Brenner W; Jenicke L; Habermann CR; Avril N; Dose-Schwarz J
    Ann Oncol; 2008 Jul; 19(7):1249-1254. PubMed ID: 18356138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.
    Schirrmeister H; Kühn T; Guhlmann A; Santjohanser C; Hörster T; Nüssle K; Koretz K; Glatting G; Rieber A; Kreienberg R; Buck AC; Reske SN
    Eur J Nucl Med; 2001 Mar; 28(3):351-8. PubMed ID: 11315604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of metastases in breast cancer patients: comparison of FDG PET with chest X-ray, bone scintigraphy and ultrasound of the abdomen].
    Dose-Schwarz J; Mahner S; Schirrmacher S; Jenicke L; Müller V; Habermann CR; Brenner W
    Nuklearmedizin; 2008; 47(3):97-103. PubMed ID: 18493688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
    J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients.
    Dose J; Bleckmann C; Bachmann S; Bohuslavizki KH; Berger J; Jenicke L; Habermann CR; Jãnicke F
    Nucl Med Commun; 2002 Sep; 23(9):857-64. PubMed ID: 12195090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.
    Riegger C; Herrmann J; Nagarajah J; Hecktor J; Kuemmel S; Otterbach F; Hahn S; Bockisch A; Lauenstein T; Antoch G; Heusner TA
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):852-63. PubMed ID: 22392069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of 18F-FDG PET/CT imaging in breast cancer staging.
    Yararbas U; Avci NC; Yeniay L; Argon AM
    Bosn J Basic Med Sci; 2018 Feb; 18(1):72-79. PubMed ID: 28763628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
    Koolen BB; Vrancken Peeters MJ; Aukema TS; Vogel WV; Oldenburg HS; van der Hage JA; Hoefnagel CA; Stokkel MP; Loo CE; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer.
    Yen TC; Ng KK; Ma SY; Chou HH; Tsai CS; Hsueh S; Chang TC; Hong JH; See LC; Lin WJ; Chen JT; Huang KG; Lui KW; Lai CH
    J Clin Oncol; 2003 Oct; 21(19):3651-8. PubMed ID: 14512397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP; David S; Alamgeer M; Ganju V
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
    Dose-Schwarz J; Tiling R; Avril-Sassen S; Mahner S; Lebeau A; Weber C; Schwaiger M; Jänicke F; Untch M; Avril N
    Br J Cancer; 2010 Jan; 102(1):35-41. PubMed ID: 19920815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?
    Botsikas D; Bagetakos I; Picarra M; Da Cunha Afonso Barisits AC; Boudabbous S; Montet X; Lam GT; Mainta I; Kalovidouri A; Becker M
    Eur Radiol; 2019 Apr; 29(4):1787-1798. PubMed ID: 30267154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer.
    van der Hoeven JJ; Krak NC; Hoekstra OS; Comans EF; Boom RP; van Geldere D; Meijer S; van der Wall E; Buter J; Pinedo HM; Teule GJ; Lammertsma AA
    J Clin Oncol; 2004 Apr; 22(7):1253-9. PubMed ID: 15051773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Smith IC; Ogston KN; Whitford P; Smith FW; Sharp P; Norton M; Miller ID; Ah-See AK; Heys SD; Jibril JA; Eremin O
    Ann Surg; 1998 Aug; 228(2):220-7. PubMed ID: 9712568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.